STAT

DECEMBER 7, 2023

But like any pharmaceutical company with an eye toward the future, Celgene continued to seek other ways to wring profits from its development work. Not long after the patent was awarded, the company leveraged federally funded research and began investigating different forms of the compound, called Revlimid.

FDA 120

FDA Compounding Pharmaceutical Companies Pharmaceutical Companies 120

European Pharmaceutical Review

FEBRUARY 27, 2024

The facility has been designed to meet the highest environmental sustainability standards, to help Amgen’s reach its target of carbon neutrality in all operations by 2027, the company noted. .” Amgen Ohio is nearly 300,000 ft 2 in size and will employ 400 full-time staff.

Pharmaceutical Companies 95

Pharmaceutical Companies Pharmaceutical Companies FDA 95

European Pharmaceutical Review

MARCH 7, 2024

billion between 2022 to 2027. Lastly, there is growing prominence and interest in radioligand therapeutics within major pharmaceutical companies, who are increasingly investing in this field, evident through recent acquisitions of Point Biopharma and RayzeBio.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Immunization FDA 52

Pharmaceutical Technology

JANUARY 10, 2023

There are multiple drugs in the pipeline, predominantly me-too and biosimilar therapies, with a significant number developed in the emerging markets of India and China by domestic pharmaceutical companies for their own rapidly growing markets.

Labelling 52

Labelling Compounding Pharmaceutical Companies Pharmaceutical Companies 52

pharmaphorum

JANUARY 16, 2023

There were developments in the past 12 months, true – Biogen/Eisai’s lecanemab (now branded Leqembi) showed clear success in the Clarity AD trial and received approval by FDA on 6th January 2023. Difficile at the end of November 2022, but in 2023 they will be joined by Seres, which expects an FDA decision in April 2023 on its C.

FDA 98

FDA Pharmaceutical Companies Pharmaceutical Companies Compounding 98

The Checkup by Singlecare

JANUARY 18, 2024

The patent protection for Nexplanon typically prevents other pharmaceutical companies from creating a generic version until the patent expires. in 2027 and other countries in 2025, when a generic version may be approved. Most insurance companies offer health insurance plans that cover Nexplanon and other birth control methods.

Insurance 52

Insurance Insurance Coverage Packaging Pharmaceutical Companies 52

Pharmaceutical Technology

FEBRUARY 6, 2023

The FDA approved both drugs in 2014. In an email , a Pliant spokesperson told Pharmaceutical Technology , “As currently approved therapies are not well tolerated, a new agent with a favorable safety profile and demonstrated efficacy would be a welcome addition to the IPF treatment armamentarium”.

FDA 59

FDA Pharmaceutical Companies Pharmaceutical Companies Communication 59